Literature DB >> 27431803

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.

Per Svenningsson1, Karin Wirdefeldt2, Li Yin2, Fang Fang2, Ioanna Markaki3, Suad Efendic4, Jonas F Ludvigsson2,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27431803     DOI： 10.1002/mds.26734

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  17 in total

1.  Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes.

Authors:  Ece Bayram; Irene Litvan
Journal:  Brain       Date:  2020-10-01       Impact factor: 13.501

2.  Does glitazone treatment have a role on the prevention of Parkinson's disease in adult diabetic population? A systematic review.

Authors:  Jesús D Meléndez-Flores; Juan Manuel Millán-Alanís; Adrián González-Martínez; Neri Alejandro Álvarez-Villalobos; Ingrid Estrada-Bellmann
Journal:  Metab Brain Dis       Date:  2020-05-04       Impact factor: 3.584

Review 3.  The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability.

Authors:  Christine Girges; Nirosen Vijiaratnam; Dilan Athauda; Grace Auld; Sonia Gandhi; Thomas Foltynie
Journal:  Drugs Aging       Date:  2021-03-19       Impact factor: 3.923

Review 4.  Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.

Authors:  Christian Hölscher
Journal:  Br J Pharmacol       Date:  2021-05-29       Impact factor: 8.739

5.  The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration.

Authors:  Yazhou Li; Elliot J Glotfelty; Tobias Karlsson; Lowella V Fortuno; Brandon K Harvey; Nigel H Greig
Journal:  J Neurochem       Date:  2021-10-21       Impact factor: 5.546

Review 6.  Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function.

Authors:  Jordan Rowlands; Julian Heng; Philip Newsholme; Rodrigo Carlessi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-23       Impact factor: 5.555

Review 7.  Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.

Authors:  Holly Green; Panagiota Tsitsi; Ioanna Markaki; Dag Aarsland; Per Svenningsson
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

Review 8.  Therapies to Slow, Stop, or Reverse Parkinson's Disease.

Authors:  Tom Foltynie; J William Langston
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

Review 9.  Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review.

Authors:  Fauze Camargo Maluf; David Feder; Alzira Alves de Siqueira Carvalho
Journal:  Parkinsons Dis       Date:  2019-11-23

Review 10.  Tackling dipeptidyl peptidase IV in neurological disorders.

Authors:  Ghaith Al-Badri; Gian Marco Leggio; Giuseppe Musumeci; Rubina Marzagalli; Filippo Drago; Alessandro Castorina
Journal:  Neural Regen Res       Date:  2018-01       Impact factor: 5.135
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.